Last checked at 24 Jul 2018 07:00
24 July 2018
Scancell Holdings Plc
("Scancell" or the "Company")
Issue of Equity
Scancell Holdings plc, ("Scancell" or the "Company") the developer of novel immunotherapies for the treatment of cancer, confirms that further to the announcement made on 18 July 2018 regarding the exercise of share options, the Company has issued, 3,184,620 new ordinary shares ("New Shares").
An application has been submitted to the London Stock Exchange for admission of the New Shares to trading on AIM. It is expected that admission will become effective and the dealings in the New Shares on AIM will commence at 8.00 a.m. on 25 July 2018 ("Admission").
The total number of ordinary shares is 387,796,556 with each ordinary share carrying the right to one vote. The Company has no shares in Treasury; therefore the total number of voting rights in Scancell is 387,796,556. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify an interest in, or change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
The New Shares will be credited as fully paid, and will, on issue, be identical to and rank pari passu in all respects with the existing ordinary shares, including the right to receive all dividends and other distributions thereafter declared, made or paid following the date of admission.
For Further Information:
Dr John Chiplin, Chairman Dr Cliff Holloway, CEO | Scancell Holdings Plc
| +44 (0) 20 3727 1000 |
Freddy Crossley/Emma Earl
| Panmure Gordon (UK) Limited | +44 (0) 20 7886 2500 |
Mo Noonan/Simon Conway | FTI Consulting | +44 (0) 20 3727 1000 |
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.
ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They can be used as monotherapy or in combination with checkpoint inhibitors. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.
· SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.
· SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK for SCIB2.
Moditope® represents a completely new class of potent and selective immunotherapy agents. It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.
· Modi-1 is being developed for the treatment of triple negative breast cancer, ovarian cancer and sarcomas.
For further details, please see our website: www.scancell.co.uk